Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or…

Read the full article here

Source: Annals of the Rheumatic Diseases

Categories: Latest Headlines, Rheumatology

Tags: Arthritis, covid19

Tweets with this article

ARD & RMD Open

Having a connective tissue disease but not inflammatory #arthritis nor its therapy increased the risk to develop severe #COVID19 in this Spanish comparative cohort study with 456 patients. https://t.co/NEWmKKRmOc https://t.co/9bBxCPqt8A

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through…

ARD & RMD Open April 19, 2024

Shift in perspective: autoimmunity protecting against rheumatoid arthritis

A hallmark of rheumatoid arthritis (RA) is the increased levels of autoantibodies preceding the onset and contributing to the classification of the disease. These autoantibodies,…

ARD & RMD Open April 18, 2024

Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events

Introduction Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown. Methods We analysed whole-blood RNA-sequencing data from…

ARD & RMD Open April 16, 2024

Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis

Background The interleukin (IL)-1 receptor accessory protein (IL1RAP) is an essential coreceptor required for signalling through the IL-1, IL-33 and IL-36 receptors. Here, we investigate…

ARD & RMD Open April 15, 2024

Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis

Objective To investigate the risk of cardiovascular disease (CVD) associated with increasing dose of a non-steroidal anti-inflammatory drug (NSAID) in patients with ankylosing spondylitis (AS).…

ARD & RMD Open April 12, 2024

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Objectives To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with…

ARD & RMD Open April 11, 2024

Primary osteoarthritis chondrocyte map of chromatin conformation reveals novel candidate effector genes

Objectives Osteoarthritis is a complex disease with a huge public health burden. Genome-wide association studies (GWAS) have identified hundreds of osteoarthritis-associated sequence variants, but the…

ARD & RMD Open April 10, 2024

HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis

The pathogenesis of axial spondyloarthritis (axSpA), although not entirely clear yet, is largely based on genes, the strongest association being with HLA-B27, importantly also in…

ARD & RMD Open April 9, 2024

Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis

Objectives The main objective was to generate a GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis and to test its reliability. To this end,…

ARD & RMD Open April 8, 2024

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Introduction Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated…

ARD & RMD Open April 5, 2024

Related Articles